Regarding the treatment method that magnetically stimulates the head called ``rTMS'', which is covered by public insurance for depression patients over the age of 18, a specialized academic society says that some medical institutions are effective in treating developmental disorders. The company issued a statement stating that the drug's effectiveness and safety in children have not been confirmed and that it is inappropriate to use it on children.
``rTMS'' is a treatment method that uses a special medical device to repeatedly apply magnetic stimulation to the head to change specific brain activities.It is used to treat depression that is not sufficiently effective with drug treatment. Public insurance is provided to patients.
Regarding this treatment, the ``Japanese Society of Child and Adolescent Psychiatry'', which is made up of child psychiatry experts, released a statement, stating that some medical institutions say it is ``effective for developmental disorders'' and that it is not recommended for children under 18 years of age. ``There is insufficient evidence of its effectiveness and safety in children, and it is not appropriate to use this treatment for developmental disorders, etc.'' ” expressed the opinion.
The statement said that guidelines from another professional society clearly state that this treatment should not be used in people under 18 years of age, and added, ``In rare cases, seizures may occur, and there are no side effects.'' "It is not a treatment that does not exist."
He also said that it would be "unethical and risky" to administer the drug to children without confirming its safety through clinical trials.
Shun Okada, the association's representative director, said, ``Entrusting a child to a treatment whose safety and effectiveness have not been fully confirmed puts the child at risk.First of all, it is important to verify its effectiveness and safety.'' I'm talking to you.